Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift - Wikidata - awgldk - TriplyDB

Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift

Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift

http://www.wikidata.org/entity/Q34160589

about

The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer's disease mice Alzheimer mechanisms and therapeutic strategies Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model.Alzheimer's therapeutics: translation of preclinical science to clinical drug development γ-Secretase inhibitors and modulators.Shift in brain metabolism in late onset Alzheimer's disease: implications for biomarkers and therapeutic interventions Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders Preclinical Alzheimer disease: identification of cases at risk among cognitively intact older individuals Therapeutic and diagnostic challenges for frontotemporal dementia At the interface of sensory and motor dysfunctions and Alzheimer's disease.Curcumin as a therapeutic agent in dementia: a mini systematic review of human studies Molecular aspects of age-related cognitive decline: the role of GABA signaling A preclinical assessment of neural stem cells as delivery vehicles for anti-amyloid therapeutics HMGB1, a pathogenic molecule that induces neurite degeneration via TLR4-MARCKS, is a potential therapeutic target for Alzheimer's disease.Crystal structure reveals conservation of amyloid-β conformation recognized by 3D6 following humanization to bapineuzumab Stem cell therapy for Alzheimer's disease and related disorders: current status and future perspectives A novel neurotrophic drug for cognitive enhancement and Alzheimer's disease Amyloid-beta (Aβ) D7H mutation increases oligomeric Aβ42 and alters properties of Aβ-zinc/copper assemblies Age-dependent neuroplasticity mechanisms in Alzheimer Tg2576 mice following modulation of brain amyloid-β levels Modeling Alzheimer's disease in mouse without mutant protein overexpression: cooperative and independent effects of Aβ and tau The anti-tumor histone deacetylase inhibitor SAHA and the natural flavonoid curcumin exhibit synergistic neuroprotection against amyloid-beta toxicity NeuroRDF: semantic integration of highly curated data to prioritize biomarker candidates in Alzheimer's disease Brain amyloid-β oligomers in ageing and Alzheimer's disease.A coimmunization vaccine of Aβ42 ameliorates cognitive deficits without brain inflammation in an Alzheimer's disease model.Has inhibition of Aβ production adequately been tested as therapeutic approach in mild AD? A model-based meta-analysis of γ-secretase inhibitor data.Biomarkers in the Diagnosis and Prognosis of Alzheimer's Disease.Imaging endpoints for clinical trials in Alzheimer's disease.Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer's Disease Patients.Pharmacological and Toxicological Properties of the Potent Oral γ-Secretase Modulator BPN-15606.Soluble Aβ oligomers are rapidly sequestered from brain ISF in vivo and bind GM1 ganglioside on cellular membranes.Scanning ultrasound removes amyloid-β and restores memory in an Alzheimer's disease mouse model.A small molecule p75NTR ligand, LM11A-31, reverses cholinergic neurite dystrophy in Alzheimer's disease mouse models with mid- to late-stage disease progression.Increased expression of PS1 is sufficient to elevate the level and activity of γ-secretase in vivo.APOE and COMT polymorphisms are complementary biomarkers of status, stability, and transitions in normal aging and early mild cognitive impairment.Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.Metal chaperones: a holistic approach to the treatment of Alzheimer's disease Targeting mitochondrial bioenergetics for Alzheimer's prevention and treatment.Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014 Plasma based markers of [11C] PiB-PET brain amyloid burden.Moving beyond anti-amyloid therapy for the prevention and treatment of Alzheimer's disease.

P2860

Q21195685-F966D992-18C1-4872-BA3E-F311C1866B12 Q22252311-6B2CA0BF-F082-41E4-89D4-5FF55D21FD36 Q24624879-C3CB65D5-44E2-4529-93E7-3AF900351407 Q26829267-4079AF8F-B1E8-4707-8EEE-90668A8301C4 Q26830462-A50EB3F6-96D0-4D8C-A6C4-DBFD8085AFC7 Q26830740-E9781305-0505-43A5-BC22-0CE533831EE1 Q26850298-73084ED8-879A-4C42-A406-F29D77E30641 Q26995405-12ECA310-6BE1-4886-B221-8FB720305BCE Q26998919-5FCAABC7-CB3B-4DA4-A713-929109CA713C Q27000410-EB76D233-B6C6-4EFE-89ED-B56FDB9E95D9 Q27012755-D9577836-F421-4733-85E2-40D90ABF14F7 Q27021454-E7F57F09-082A-430F-B3D4-CF12018D82AE Q27305517-229FA3CA-760B-440D-8895-D7E9DB6AB28C Q27315985-16C580F3-7014-45B1-8942-45FF9B4A53D2 Q27684692-9C1FCC51-C7BA-46AE-A6C9-8B9F8EF40245 Q28085612-2E790D40-2E15-4A4F-B3CF-2F9BE1711921 Q28478380-7BEE33B6-4039-4F87-B01F-BB1A78F2F36F Q28483048-C0170E5C-9D49-40B1-8F9A-A0D0D4834501 Q28488088-75B01CEE-81A2-4EEE-8A13-9DC8CEBCAED8 Q28535293-00C26FB9-296F-4219-A97A-A5ED2234B2FD Q28538399-85A09FC7-0E54-46CE-A3BA-B182FA768135 Q28596503-74285B72-5EC3-45FC-AF21-37FD405B108C Q30539133-B635339A-1823-4F4E-BC18-D1467210DFB1 Q30581976-D07585B2-4732-439A-9D22-EADC1D09BE6D Q30584453-ED31ACA2-D26E-42B8-83F3-96886E74CEE8 Q30871982-AF1DB253-6353-45F3-A85E-0C7D6C7AD32D Q30885979-43331B4D-9270-4BE6-8F08-3A338A48595F Q31171988-2B093790-5CE3-48FE-89F5-7BB5C5383641 Q33754484-CD94DF54-9C11-406A-9454-45A786180AD6 Q34031193-15845258-3B2B-4E93-8B8F-A989847B8FFB Q34043432-527B4082-8D6F-41C7-9C4E-4883771A7ABD Q34083364-34D2B56B-6CD9-4566-AD68-7A8265A75D55 Q34091318-AB9B9957-CE10-41D5-9CF2-44E1262C67B8 Q34139700-2F14BFA7-7E13-4123-AE2F-05EA4BE28829 Q34157492-57594B94-7A50-4791-BE79-8596B32EF13B Q34260002-520E6C04-4DDE-4C0F-B02B-B627B5D143AD Q34407220-4E451FAE-FC85-4D28-9572-134E6A261EF0 Q34408888-F9F936AF-CD35-4C66-B761-E1087C5DD235 Q34427001-528E53E8-0E2B-40E3-9BA3-EBEB7DC15F54 Q34538592-57EF8292-93B9-4085-BC90-D0556E4D1EF6

P2860

Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift

http://www.wikidata.org/entity/Q34160589

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift

@ast

Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift

@en

Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift

@nl

type

label

Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift

@ast

Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift

@en

Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift

@nl

prefLabel

Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift

@ast

Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift

@en

Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift

@nl

P1433

Q34160589-213BE096-CFAB-4D45-A80B-7B74DFC64AD2

P1476

Q34160589-5DB50606-E7E1-4CCE-9D3A-434370D3470C

P2093

Q34160589-396CB3A6-B2D6-4187-A4BF-A472999E5971

Q34160589-B8DE783F-2D85-4C2A-9CCA-6E708FEE7A82

Q34160589-F1E36564-14FF-4263-AA5A-638A7662A73A

P2860

Q34160589-00B32687-9715-46EB-A75E-F6557C60866F

Q34160589-03E04916-64D6-4B93-9C01-37023D7D8509

Q34160589-0A34E704-0EEC-4F1A-9DC9-4FDB867DCC41

Q34160589-0E4EF481-F17B-4ED1-BD9C-7CFABC8752FB

Q34160589-19FA2B0B-5A42-474B-99D4-C3009BB0A14B

Q34160589-1A03D047-5933-4B08-9EA8-3DDF50251FF4

Q34160589-23B77505-8350-404D-8517-84351EE86699

Q34160589-24945153-D40F-4F02-811F-DBD6E0BCC100

Q34160589-2A9AA167-42B8-4CD5-A345-F791AA316036

Q34160589-2ADC17A1-819D-4898-AA62-8E68FDF81532

P304

Q34160589-0029DAD4-6890-4B41-9F5D-778A17A426E5

P31

Q34160589-C2D09C71-E036-43CF-82CF-F146BF13BDC8

P356

Q34160589-5ACB55E2-008C-4870-A434-47B2627FE002

P407

Q34160589-E2FFD531-853B-4F4D-87DB-D8C4FF6CF388

P433

Q34160589-E7F4F48C-3696-40DB-AA59-3A650C7CDEF5

P478

Q34160589-7158653E-F934-4A72-84E0-AA2B9740EBBB

P577

Q34160589-223A115A-B81A-42EE-80FD-AEEBE3AE0102

P5875

Q34160589-4E37BAB8-63CE-4FDD-86AD-99217C3C7132

P698

Q34160589-FC6453E3-F86F-428E-9674-336D154D311E

P921

Q34160589-52C05923-2EBA-4FD1-92C8-C5FCCE02CF1D

P932

Q34160589-9E13D3F0-EC4B-459E-9AE3-DAB5116BC2F7

P356

J.NEURON.2011.01.002

P1433

P1476

Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift

@en

P2093

Edward H Koo

http://www.w3.org/2001/XMLSchema#string

Lon S Schneider

http://www.w3.org/2001/XMLSchema#string

Todd E Golde

http://www.w3.org/2001/XMLSchema#string

P2860

Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials

Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people

Apolipoprotein E and Alzheimer disease

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

Alzheimer's disease: genes, proteins, and therapy

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium

Protein aggregation and neurodegenerative disease

Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study

P304

203-213

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.NEURON.2011.01.002

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

69

http://www.w3.org/2001/XMLSchema#string

P577

2011-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49781253

http://www.w3.org/2001/XMLSchema#string

P698

21262461

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

3058906

http://www.w3.org/2001/XMLSchema#string